|
Market Closed -
Nasdaq
21:00:00 05/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 223.59 USD | +1.69% |
|
-2.23% | +27.05% |
| 10-02 | Biogen's experimental lupus drug shows benefit against skin symptoms | RE |
| 10-02 | Biogen Says Litifilimab Shows Efficacy in New 52-Week Phase 2 Data | MT |
Company Valuation: Biogen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,242 | 39,877 | 37,495 | 22,283 | 25,818 | 33,036 | - | - |
| Change | - | 13.15% | -5.97% | -40.57% | 15.86% | 27.96% | - | - |
| Enterprise Value (EV) 1 | 37,820 | 40,560 | 43,384 | 26,204 | 28,289 | 37,973 | 35,456 | 32,384 |
| Change | - | 7.24% | 6.96% | -39.6% | 7.96% | 34.23% | -6.63% | -8.66% |
| P/E | 23.1x | 13.3x | 32.5x | 13.7x | 20x | 36.5x | 19.8x | 16x |
| PBR | 3.26x | 3.02x | 2.53x | 1.33x | 1.42x | 1.79x | 1.62x | 1.47x |
| PEG | - | 0x | -0.5x | 0.3x | -0.9x | -1.2x | 0.2x | 0.7x |
| Capitalization / Revenue | 3.21x | 3.92x | 3.81x | 2.3x | 2.61x | 3.16x | 3.1x | 3.02x |
| EV / Revenue | 3.44x | 3.99x | 4.41x | 2.71x | 2.86x | 3.64x | 3.33x | 2.96x |
| EV / EBITDA | 9.13x | 11.2x | 14.3x | 7.1x | 7.82x | 13.6x | 10.2x | 8.79x |
| EV / EBIT | 10.3x | 13.1x | 17x | 8.69x | 9.97x | 15.1x | 11.1x | 9.22x |
| EV / FCF | 11.2x | 35.5x | 34.2x | 9.63x | 13.8x | 20.2x | 14.1x | 11.4x |
| FCF Yield | 8.94% | 2.82% | 2.93% | 10.4% | 7.25% | 4.96% | 7.09% | 8.81% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 10.4 | 20.87 | 7.97 | 11.18 | 8.79 | 6.131 | 11.31 | 13.94 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 | 10,446 | 10,658 | 10,955 |
| EBITDA 1 | 4,144 | 3,618 | 3,040 | 3,689 | 3,618 | 2,785 | 3,467 | 3,683 |
| EBIT 1 | 3,656 | 3,099 | 2,545 | 3,015 | 2,838 | 2,514 | 3,209 | 3,512 |
| Net income 1 | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 | 998.8 | 1,860 | 2,197 |
| Net Debt 1 | 2,578 | 683 | 5,888 | 3,921 | 2,471 | 4,937 | 2,420 | -652.2 |
| Reference price 2 | 239.92 | 276.92 | 258.77 | 152.92 | 175.99 | 223.59 | 223.59 | 223.59 |
| Nbr of stocks (in thousands) | 146,893 | 144,001 | 144,898 | 145,719 | 146,702 | 147,754 | - | - |
| Announcement Date | 03/02/22 | 15/02/23 | 13/02/24 | 12/02/25 | 06/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 36.47x | 3.64x | 13.64x | -.--% | 33.04B | |
| 32.46x | 11.79x | 23.8x | 0.61% | 1,019B | |
| 28.13x | 6.24x | 17.86x | 2.11% | 610B | |
| 33.64x | 7.86x | 16.24x | 2.61% | 470B | |
| 101.52x | 5.7x | 24.22x | 2.45% | 344B | |
| 18.95x | 4.61x | 11.45x | 2.87% | 336B | |
| 19.74x | 5.16x | 12.75x | 3.1% | 266B | |
| 19.84x | 4.13x | 11.77x | 2.15% | 241B | |
| 25.45x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.74x | 6.39x | 24.95x | 2.28% | 179B | |
| Average | 27.25x | 6.22x | 16.85x | 2.07% | 371.59B | |
| Weighted average by Cap. | 31.29x | 7.56x | 18.49x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BIIB Stock
- Valuation Biogen Inc.
Select your edition
All financial news and data tailored to specific country editions
